Oncology
5 drugs are in development for Triple Negative Breast Cancer.
- Companies
- 5
- Clinical trials
- 66
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Triple Negative Breast Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(4)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| tc-510 | TCR2 THERAPEUTICS INC. (TCRR) |
About this indication
Triple Negative Breast Cancer context
Oncology·MeSH: Triple Negative Breast Neoplasms (D064726)
Also known as: Breast Cancers, Triple-Negative, Breast Neoplasm, Triple-Negative, Breast Neoplasms, Triple-Negative, ER Negative PR Negative HER2 Negative Breast Cancer, ER Negative PR Negative HER2 Negative Breast Neoplasms
Prevalence
34.0 / 100K
Incidence
15.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Triple Negative Breast Cancer?
BioSniper tracks 5 drugs in development for Triple Negative Breast Cancer across 5 companies.
How many clinical trials target Triple Negative Breast Cancer?
There are 66 clinical trials targeting Triple Negative Breast Cancer tracked by BioSniper.
What is the prevalence of Triple Negative Breast Cancer?
The estimated prevalence of Triple Negative Breast Cancer is approximately 34.0 per 100,000 population.